ImmunoGen Jumps on earnings beat

NASDAQ:IMGN   ImmunoGen, Inc

Possible entry level $7.21 or on pullback to $6.05
Target price $8.96 - $10
ImmunoGen ( IMGN ) Q4 results:
Revenues: $44.9M (+235.1%).
Net Income: $4.8M (+111.5%); EPS: $0.03 (+110.7%); Quick Assets: $176.2M (-32.8%).
2020 guidance: Revenues: $60M - 65M.

Transition next generation anti-fol-ate receptor alpha ( ADC , IMGN151, to pre-clinical development in mid-2020.
Source seeking alpha
ImmunoGen , Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

⭐Email Newsletter > https://www.BullishCharts.com/

🔵Telegram Channel > https://t.me/BullishCharts

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.